(Q33662027)

28 July 2017

1 reference

title

Medical therapy of specific clinical presentations (English)

1 reference

28 July 2017

Michetti P

1

1 reference

28 July 2017

Peppercorn MA

series ordinal

2

1 reference

28 July 2017

publication date

1 June 1999

1 reference

Gastroenterology Clinics of North America

28 July 2017

published in

1 reference

28 July 2017

volume

28

1 reference

28 July 2017

issue

2

1 reference

28 July 2017

page(s)

353-70, viii

1 reference

Endoscopic and bioptic findings in the upper gastrointestinal tract in patients with Crohn's disease

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Oral fluticasone propionate in active distal ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Pharmacological aspects of therapy in inflammatory bowel diseases: antidiarrheal agents

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Crohn's disease. A long-term study of the clinical course in 186 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Final report on a placebo-controlled, double-blind, randomized, multicentre trial of cyclosporin treatment in active chronic Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

The efficacy of tobramycin in the treatment of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

A controlled double blind study of azathioprine in the management of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Prognostic factors for postoperative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Intravenous cyclosporine in attacks of ulcerative colitis: short-term and long-term responses

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Intermittent therapy with high-dose 5-aminosalicylic acid enemas for maintaining remission in ulcerative proctosigmoiditis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

A controlled randomized trial of budesonide versus prednisolone retention enemas in active distal ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

A steroid enema, budesonide, lacking systemic effects for the treatment of distal ulcerative colitis or proctitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

CONTROLLED TRIAL OF SULPHASALAZINE IN THE TREATMENT OF ULCERATIVE COLITIS.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Mesalazine suppositories versus hydrocortisone foam in patients with distal ulcerative colitis. A comparison of the efficacy and practicality of two topical treatment regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Low-Dose Cyclosporine for the Treatment of Crohn's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Methotrexate for the Treatment of Crohn's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

A comparative study of metronidazole and sulfasalazine in active, not severe, ulcerative colitis. An Israeli multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Controlled trial of bowel rest and nutritional support in the management of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Combination ciprofloxacin and metronidazole for active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Meta-analysis of enteral nutrition as a primary treatment of active crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The U.S. PENTASA Enema Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Randomised controlled trial of azathioprine withdrawal in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Use of antidiarrheals in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Mycobacterium paratuberculosis cervical lymphadenitis, followed five years later by terminal ileitis similar to Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Availability of mesalazine (5-aminosalicylic acid) from enemas and suppositories during steady-state conditions

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Intensive intravenous treatment of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Endoscopic balloon dilatation of duodenal strictures in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Controlled trial of azathioprine in chronic ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Favorable effect of 6-mercaptopurine on fistulae of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Clinical course of colorectal Crohn's disease: a 35-year follow-up study of 507 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Preoperative total parenteral nutrition for bowel resection in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Delivery and fate of oral mesalamine microgranules within the human small intestine

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Methotrexate for the treatment of refractory Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Cyclosporine in severe ulcerative colitis refractory to steroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

The role of azathioprine in the management of ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Comparison of enteral nutrition and drug treatment in active Crohn's disease. Results of the European Cooperative Crohn's Disease Study. IV.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Budesonide versus prednisolone retention enemas in active distal ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Response to azathioprine in ulcerative colitis. Report of 7 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Controlled trial of oligopeptide versus amino acid diet in treatment of active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Long-term outcome of endoscopic balloon dilation in obstructive gastroduodenal Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Perianal Crohn's disease--is it all bad news?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

High incidence of upper gastrointestinal tract involvement in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Toxic megacolon: the knee-elbow position relieves bowel distension

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Antibiotics are effective therapy for Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

A Controlled Comparison of Corticotropin and Hydrocortisone in the Treatment of Severe Proctocolitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Efficacy of cyclosporine in treatment of fistula of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Medical decompression of toxic megacolon by "rolling". A new technique of decompression with favorable long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Symptoms and stool patterns in patients with ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Controlled trial of azathioprine in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

A controlled trial of azathioprine in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

High-dose methylprednisolone in the treatment of active ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

A comparison of budesonide with prednisolone for active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

The problem of postoperative recurrence of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Maintenance therapy in ulcerative colitis and Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

[Metronidazole in the treatment of Crohn disease. Results of a controlled randomized prospective study]

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Sulfasalazine-Induced Exacerbation of Ulcerative Colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Use of an intravenous steroid regimen in the treatment of acute Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Second trial of mesalamine therapy in the treatment of active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Favorable response to parenteral nutrition and medical therapy in Crohn's colitis. A report of 38 patients comparing severe Crohn's and ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

The dilemma of Crohn's disease: long-term follow-up of Crohn's disease of the small intestine

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Double blind, placebo controlled trial of metronidazole in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

5-Aminosalicylic acid enemas in treatment of distal ulcerative colitis and proctitis in Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Transdermal nicotine as maintenance therapy for ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

Peripheral parenteral nutrition is no better than enteral nutrition in acute exacerbation of Crohn's disease: a prospective trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970060-1

7 January 2021

10.1016/S0889-8553(05)70060-1

Identifiers

DOI

1 reference

28 July 2017

1 reference